Review





Similar Products

96
Miltenyi Biotec cd4 apc vio770
Cd4 Apc Vio770, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd4+apc/CD4+Antibody%2C+anti-human%2C+REAfinity/pm42985785-64-19-38
Average 96 stars, based on 1 article reviews
cd4 apc vio770 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

94
Elabscience Biotechnology cd4
Combination therapy activates innate immunity via the STING-TBK1-IRF3-IFNβ pathway and enhances T-cell function. (A) Western blot analysis of STING pathway components (TBK1, p-TBK1, p-IRF3, IFNβ, NF-κB) in H82R and H526R cells. (B) Schematic illustration of the multicellular tumor spheroid (MCT) model composed of H82R SCLC cells, MRC-5 fibroblasts, HUVECs, and PBMCs. (C) Representative bright-field images of MCTs after treatment. Scale bar, 100 μm. (D) Flow cytometry analysis of CD8 + cytotoxic T cells, <t>CD4</t> + helper T cells, and CD45 + HLA-DR + activated immune cells in MCTs (left) and quantification of cell percentages (right). All experiments were performed independently three times. n = 3 biologically independent replicates. The Student’s t-test was used to estimate the significance of the difference between two groups. Comparisons among multiple groups were performed by one-way ANOVA followed by Tukey’s post hoc test. Data were presented as means ± s.d. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant.
Cd4, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd4+apc/APC+Anti-Human+CD8a+Antibody/pmc13774206-48-18-20
Average 94 stars, based on 1 article reviews
cd4 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

93
Miltenyi Biotec apc conjugated anti cd4
Combination therapy activates innate immunity via the STING-TBK1-IRF3-IFNβ pathway and enhances T-cell function. (A) Western blot analysis of STING pathway components (TBK1, p-TBK1, p-IRF3, IFNβ, NF-κB) in H82R and H526R cells. (B) Schematic illustration of the multicellular tumor spheroid (MCT) model composed of H82R SCLC cells, MRC-5 fibroblasts, HUVECs, and PBMCs. (C) Representative bright-field images of MCTs after treatment. Scale bar, 100 μm. (D) Flow cytometry analysis of CD8 + cytotoxic T cells, <t>CD4</t> + helper T cells, and CD45 + HLA-DR + activated immune cells in MCTs (left) and quantification of cell percentages (right). All experiments were performed independently three times. n = 3 biologically independent replicates. The Student’s t-test was used to estimate the significance of the difference between two groups. Comparisons among multiple groups were performed by one-way ANOVA followed by Tukey’s post hoc test. Data were presented as means ± s.d. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant.
Apc Conjugated Anti Cd4, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd4+apc/CD4+Antibody%2C+anti-human/pmc13771249-36-31-35
Average 93 stars, based on 1 article reviews
apc conjugated anti cd4 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
Elabscience Biotechnology cd4 apc
Combination therapy activates innate immunity via the STING-TBK1-IRF3-IFNβ pathway and enhances T-cell function. (A) Western blot analysis of STING pathway components (TBK1, p-TBK1, p-IRF3, IFNβ, NF-κB) in H82R and H526R cells. (B) Schematic illustration of the multicellular tumor spheroid (MCT) model composed of H82R SCLC cells, MRC-5 fibroblasts, HUVECs, and PBMCs. (C) Representative bright-field images of MCTs after treatment. Scale bar, 100 μm. (D) Flow cytometry analysis of CD8 + cytotoxic T cells, <t>CD4</t> + helper T cells, and CD45 + HLA-DR + activated immune cells in MCTs (left) and quantification of cell percentages (right). All experiments were performed independently three times. n = 3 biologically independent replicates. The Student’s t-test was used to estimate the significance of the difference between two groups. Comparisons among multiple groups were performed by one-way ANOVA followed by Tukey’s post hoc test. Data were presented as means ± s.d. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant.
Cd4 Apc, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd4+apc/APC+Anti-Mouse+CD4+Antibody/pm42909153-503-21-23
Average 94 stars, based on 1 article reviews
cd4 apc - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

96
Miltenyi Biotec anti cd4 apc
Combination therapy activates innate immunity via the STING-TBK1-IRF3-IFNβ pathway and enhances T-cell function. (A) Western blot analysis of STING pathway components (TBK1, p-TBK1, p-IRF3, IFNβ, NF-κB) in H82R and H526R cells. (B) Schematic illustration of the multicellular tumor spheroid (MCT) model composed of H82R SCLC cells, MRC-5 fibroblasts, HUVECs, and PBMCs. (C) Representative bright-field images of MCTs after treatment. Scale bar, 100 μm. (D) Flow cytometry analysis of CD8 + cytotoxic T cells, <t>CD4</t> + helper T cells, and CD45 + HLA-DR + activated immune cells in MCTs (left) and quantification of cell percentages (right). All experiments were performed independently three times. n = 3 biologically independent replicates. The Student’s t-test was used to estimate the significance of the difference between two groups. Comparisons among multiple groups were performed by one-way ANOVA followed by Tukey’s post hoc test. Data were presented as means ± s.d. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant.
Anti Cd4 Apc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd4+apc/CD4+Antibody%2C+anti-human%2C+REAfinity/pmc13636363-49-33-36
Average 96 stars, based on 1 article reviews
anti cd4 apc - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
Miltenyi Biotec cd4 apc
Combination therapy activates innate immunity via the STING-TBK1-IRF3-IFNβ pathway and enhances T-cell function. (A) Western blot analysis of STING pathway components (TBK1, p-TBK1, p-IRF3, IFNβ, NF-κB) in H82R and H526R cells. (B) Schematic illustration of the multicellular tumor spheroid (MCT) model composed of H82R SCLC cells, MRC-5 fibroblasts, HUVECs, and PBMCs. (C) Representative bright-field images of MCTs after treatment. Scale bar, 100 μm. (D) Flow cytometry analysis of CD8 + cytotoxic T cells, <t>CD4</t> + helper T cells, and CD45 + HLA-DR + activated immune cells in MCTs (left) and quantification of cell percentages (right). All experiments were performed independently three times. n = 3 biologically independent replicates. The Student’s t-test was used to estimate the significance of the difference between two groups. Comparisons among multiple groups were performed by one-way ANOVA followed by Tukey’s post hoc test. Data were presented as means ± s.d. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant.
Cd4 Apc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd4+apc/CD4+Antibody%2C+anti-mouse/10__1038_slash_s41398___026___04497___2-166-39-40
Average 96 stars, based on 1 article reviews
cd4 apc - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

93
Miltenyi Biotec apc rea823 miltenyi biotec cd34 apc rea1164 miltenyi biotec cd4 pe
Combination therapy activates innate immunity via the STING-TBK1-IRF3-IFNβ pathway and enhances T-cell function. (A) Western blot analysis of STING pathway components (TBK1, p-TBK1, p-IRF3, IFNβ, NF-κB) in H82R and H526R cells. (B) Schematic illustration of the multicellular tumor spheroid (MCT) model composed of H82R SCLC cells, MRC-5 fibroblasts, HUVECs, and PBMCs. (C) Representative bright-field images of MCTs after treatment. Scale bar, 100 μm. (D) Flow cytometry analysis of CD8 + cytotoxic T cells, <t>CD4</t> + helper T cells, and CD45 + HLA-DR + activated immune cells in MCTs (left) and quantification of cell percentages (right). All experiments were performed independently three times. n = 3 biologically independent replicates. The Student’s t-test was used to estimate the significance of the difference between two groups. Comparisons among multiple groups were performed by one-way ANOVA followed by Tukey’s post hoc test. Data were presented as means ± s.d. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant.
Apc Rea823 Miltenyi Biotec Cd34 Apc Rea1164 Miltenyi Biotec Cd4 Pe, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd4+apc/CD34+Antibody%2C+anti-human%2C+REAfinity/10__1016_slash_j__bict__2026__100105-478-94-96
Average 93 stars, based on 1 article reviews
apc rea823 miltenyi biotec cd34 apc rea1164 miltenyi biotec cd4 pe - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
Elabscience Biotechnology apc antimouse cd4 antibody
Combination therapy activates innate immunity via the STING-TBK1-IRF3-IFNβ pathway and enhances T-cell function. (A) Western blot analysis of STING pathway components (TBK1, p-TBK1, p-IRF3, IFNβ, NF-κB) in H82R and H526R cells. (B) Schematic illustration of the multicellular tumor spheroid (MCT) model composed of H82R SCLC cells, MRC-5 fibroblasts, HUVECs, and PBMCs. (C) Representative bright-field images of MCTs after treatment. Scale bar, 100 μm. (D) Flow cytometry analysis of CD8 + cytotoxic T cells, <t>CD4</t> + helper T cells, and CD45 + HLA-DR + activated immune cells in MCTs (left) and quantification of cell percentages (right). All experiments were performed independently three times. n = 3 biologically independent replicates. The Student’s t-test was used to estimate the significance of the difference between two groups. Comparisons among multiple groups were performed by one-way ANOVA followed by Tukey’s post hoc test. Data were presented as means ± s.d. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant.
Apc Antimouse Cd4 Antibody, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd4+apc/APC+Anti-Mouse+CD4+Antibody/10__1016_slash_j__cej__2026__180001-105-17-22
Average 94 stars, based on 1 article reviews
apc antimouse cd4 antibody - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

Image Search Results


Combination therapy activates innate immunity via the STING-TBK1-IRF3-IFNβ pathway and enhances T-cell function. (A) Western blot analysis of STING pathway components (TBK1, p-TBK1, p-IRF3, IFNβ, NF-κB) in H82R and H526R cells. (B) Schematic illustration of the multicellular tumor spheroid (MCT) model composed of H82R SCLC cells, MRC-5 fibroblasts, HUVECs, and PBMCs. (C) Representative bright-field images of MCTs after treatment. Scale bar, 100 μm. (D) Flow cytometry analysis of CD8 + cytotoxic T cells, CD4 + helper T cells, and CD45 + HLA-DR + activated immune cells in MCTs (left) and quantification of cell percentages (right). All experiments were performed independently three times. n = 3 biologically independent replicates. The Student’s t-test was used to estimate the significance of the difference between two groups. Comparisons among multiple groups were performed by one-way ANOVA followed by Tukey’s post hoc test. Data were presented as means ± s.d. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant.

Journal: Frontiers in Pharmacology

Article Title: Anlotinib suppresses homologous recombination via the E2F8-RAD51 axis to activate STING immunity and potentiate PARP inhibitor synthetic lethality in resistant small cell lung cancer

doi: 10.3389/fphar.2026.1939827

Figure Lengend Snippet: Combination therapy activates innate immunity via the STING-TBK1-IRF3-IFNβ pathway and enhances T-cell function. (A) Western blot analysis of STING pathway components (TBK1, p-TBK1, p-IRF3, IFNβ, NF-κB) in H82R and H526R cells. (B) Schematic illustration of the multicellular tumor spheroid (MCT) model composed of H82R SCLC cells, MRC-5 fibroblasts, HUVECs, and PBMCs. (C) Representative bright-field images of MCTs after treatment. Scale bar, 100 μm. (D) Flow cytometry analysis of CD8 + cytotoxic T cells, CD4 + helper T cells, and CD45 + HLA-DR + activated immune cells in MCTs (left) and quantification of cell percentages (right). All experiments were performed independently three times. n = 3 biologically independent replicates. The Student’s t-test was used to estimate the significance of the difference between two groups. Comparisons among multiple groups were performed by one-way ANOVA followed by Tukey’s post hoc test. Data were presented as means ± s.d. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant.

Article Snippet: After treatment, MCTs were dissociated into single cells and stained with fluorescently labeled antibodies against CD8 (E-AB-F1109C, Elabscience), CD4 (E-AB-F1110E, Elabscience), CD45 (E-AB-F1137F, Elabscience) and HLA-DR (E-AB-F1111D, Elabscience).

Techniques: Cell Function Assay, Western Blot, Analysis, Flow Cytometry